Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
stocks
The 10 best US dividend shares
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,579.90 | 50.10 | 0.59% |
| CAC 40 | 7,886.69 | 33.22 | 0.42% |
| DAX 40 | 23,767.43 | 71.84 | 0.30% |
| Dow JONES (US) | 42,654.74 | 331.99 | 0.78% |
| FTSE 100 | 8,684.56 | 50.81 | 0.59% |
| HKSE | 23,345.05 | 108.11 | -0.46% |
| NASDAQ | 19,211.10 | 98.78 | 0.52% |
| Nikkei 225 | 37,753.72 | 1.79 | -0.00% |
| NZX 50 Index | 12,786.79 | 94.03 | -0.73% |
| S&P 500 | 5,958.38 | 41.45 | 0.70% |
| S&P/ASX 200 | 8,343.70 | 46.20 | 0.56% |
| SSE Composite Index | 3,367.46 | 13.36 | -0.40% |